Treatment of Brachial Vein Deep Vein Thrombosis (DVT)

Initial Management

The American College of Chest Physicians recommends anticoagulation should be initiated immediately upon diagnosis of brachial vein DVT, with low molecular weight heparin (LMWH) or fondaparinux preferred over intravenous unfractionated heparin (IV UFH) for initial treatment 1, 3
For patients transitioning to vitamin K antagonists (VKAs), parenteral anticoagulation should be continued for a minimum of 5 days and until the INR is ≥2.0 for at least 24 hours, according to the American College of Chest Physicians 3
Outpatient treatment is appropriate for patients with adequate home circumstances and without significant comorbidities, as recommended by the American College of Chest Physicians 3

The American College of Chest Physicians recommends direct oral anticoagulants (DOACs) such as apixaban, dabigatran, edoxaban, or rivaroxaban over VKAs for the treatment phase 3
In patients with cancer-associated brachial vein thrombosis, oral factor Xa inhibitors (apixaban, edoxaban, rivaroxaban) are recommended over LMWH by the American College of Chest Physicians 3

For brachial vein DVT not associated with a central venous catheter, a minimum duration of 3 months of anticoagulation is recommended by the American College of Chest Physicians 5
For catheter-related brachial vein DVT, if the catheter is removed, 3 months of anticoagulation is recommended for patients without cancer, according to the American College of Chest Physicians 5
If the catheter remains in place, anticoagulation should continue as long as the catheter is present, as recommended by the National Comprehensive Cancer Network and the American College of Chest Physicians 1, 5

Catheter removal is not necessary if it is functional, free of infection, and still required for clinical care, according to the National Comprehensive Cancer Network and the American College of Chest Physicians 1, 5
Thrombolysis is generally not recommended for routine treatment of upper extremity DVT, but may be considered in select patients who are likely to benefit, have access to catheter-directed thrombolysis, and place high value on preventing post-thrombotic syndrome, as stated by the American College of Chest Physicians 5

For patients on DOACs, routine monitoring of coagulation parameters is not required, according to the American College of Chest Physicians 3
For patients on VKAs, regular INR monitoring is needed to maintain a therapeutic range of 2.0-3.0 (target INR 2.5), as recommended by the American College of Chest Physicians 3

DOACs may not be appropriate for patients with severe renal impairment, as they are primarily eliminated through the kidneys, according to the National Comprehensive Cancer Network 1
For pregnant patients, DOACs are contraindicated; LMWH is the preferred anticoagulant, as recommended by the Mayo Clinic 6